In:
Pharmacogenomics, Future Medicine Ltd, Vol. 2, No. 3 ( 2001-08-01), p. 303-305
Abstract:
Pharmacogenomics promises to offer distinct strategic advantages to pharmaceutical companies, physicians, providers and patients. Cambridge Healthtech Institute’s 2nd Annual Conference on ‘Pharmacogenomics Europe: Presaging Profits’ covered all aspects of pharmacogenomics and gave scientists from both academia and from pharmaceutical and biotech companies a great opportunity to discuss the latest progress in pharmacogenomic research. The meeting considered technologies for single nucleotide polymorphism (SNP) screening and expression profiling, bioinformatic tools for data evaluation and gave an overview on the state of affairs and novel approaches to implement pharmacogenomics and pharmacogenetics into drug development and medical treatment. The major strength of the meeting was the merging of scientists from many differnt discipines, such as clinicians, pharmacologists, molecular biologists, engineers and bioinformatics experts, into one meeting.
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
DOI:
10.1517/14622416.2.3.303
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2001
SSG:
15,3
